Harvest Portfolios Group Inc. Has $60.47 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Harvest Portfolios Group Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 107,547 shares of the biopharmaceutical company’s stock after acquiring an additional 8,547 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.1% of Harvest Portfolios Group Inc.’s holdings, making the stock its 27th largest position. Harvest Portfolios Group Inc. owned approximately 0.10% of Regeneron Pharmaceuticals worth $60,470,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at $34,000. Traub Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $38,000. Finally, Berbice Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 300.0% during the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on REGN. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Finally, Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA expanded Dupixent’s label — the U.S. approved Dupixent (dupilumab) for allergic fungal rhinosinusitis in patients aged 6 and older, widening the drug’s approved uses and pediatric market potential. Read More.
• Positive Sentiment: EU recommendation for pediatric CSU approval — the EMA recommended Dupixent for chronic spontaneous urticaria in children aged 2–11, which would make Dupixent the first targeted EU therapy for that age group and further supports franchise growth alongside Sanofi. Read More.
• Positive Sentiment: Analyst/market upgrades — Wall Street Zen raised REGN to a Buy rating, reflecting renewed analyst optimism that can drive additional demand for the shares. Read More.
• Positive Sentiment: Dupixent remains a growth engine — coverage notes Dupixent sales grew strongly (year‑over‑year growth in Q4), reinforcing expectations that REGN’s near‑term revenue and margins will keep improving. Read More.
• Positive Sentiment: Institutional interest in gene-therapy/biotech exposure — hedge‑fund lists and roundups continue to single out Regeneron as a top gene‑therapy/biotech pick, supporting longer‑term investor appetite. Read More.
• Neutral Sentiment: Relative performance context — some commentary notes REGN has lagged the Nasdaq over the past year even as analysts remain bullish; this frames the rally as partly a catch‑up rather than an outright re‑rating. Read More.

Insider Buying and Selling

In other news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 in the last quarter. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $781.67 on Friday. The firm has a market cap of $82.64 billion, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 2.07 and a beta of 0.40. The company’s fifty day moving average is $771.59 and its 200-day moving average is $680.78. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.